Skip to content

Psilocybin for depression: all studies

Page 42 of 49: studies 411 to 420 of 490, newest first. Back to the psilocybin for depression overview

Research

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

Journal of Neurochemistry September 14, 2021 Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr et al. 78 citations

Abstract The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability to improve the debilitating symptoms of major depressive disorder (MDD) long‐term after only a single treatment. Indeed, the Food and Drug...

The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research

Journal of Holistic Nursing September 6, 2021 Rebecca H Lehto, Megan Miller, Jessica Sender 16 citations

Treatments for addressing psychiatric mental health issues in vulnerable patients with cancer are established. Yet, many patients persist with unrelenting psychological difficulties despite intervention. There is growing interest in the role of psilocybin-assisted psychotherapy for managing treatment-resistant mental health challenges in patients with cancer. Psilocybin is a naturally occurring...

Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review

Research Society and Development August 19, 2021 Frederico Marques Silveira, Amanda Pereira Mendes, Mayara Rodrigues Dos Santos et al. 1 citation

Cancer is not limited to the physical dimension, but it also affects the entire biopsychosocial context in which the patient is inserted, making him more susceptible to psychiatric disorders such as depression and anxiety. These often require pharmacological intervention, and the use of psilocybin, a substance found in mushroom species, is one of the alternatives considered today. The present...

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review

Pharmaceuticals August 12, 2021 Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza et al. 30 citations

Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this...

[Efficacy of psychedelics in psychiatry, a systematic review of the literature].

L'Encephale August 1, 2021 Lucie Berkovitch, Bruno Romeo, Laurent Karila et al. 25 citations

Psychedelics are powerful psychoactive substances. Natural psychedelics have been used for millennia by human civilizations, in particular in Latin America, while synthetic psychedelics were discovered in the 50s, giving rise to a lot of research before they were prohibited. More recently, their therapeutic properties have been studied especially to help patients with psychiatric conditions,...

The Potential Role of Serotonergic Hallucinogens in Depression Treatment

Life July 29, 2021 Dominika Psiuk, Emilia Nowak, Krystian Cholewa et al. 13 citations

Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic...

Registered clinical studies investigating psychedelic drugs for psychiatric disorders.

Journal of Psychiatric Research July 1, 2021 Ashley N. Siegel, Shakila Meshkat, Katie Benitah et al. 101 citations

Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies has risen significantly. In this paper, clinical studies registered on clinicaltrials.gov that evaluate the treatment...